{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:05:23Z","timestamp":1775059523343,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T00:00:00Z","timestamp":1659830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T00:00:00Z","timestamp":1659830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"China National Major Project for New Drug Innovation","award":["2017ZX09304015"],"award-info":[{"award-number":["2017ZX09304015"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-2019AZMS-0439"],"award-info":[{"award-number":["Y-2019AZMS-0439"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00262-022-03251-z","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T17:02:42Z","timestamp":1659891762000},"page":"449-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients"],"prefix":"10.1007","volume":"72","author":[{"given":"Yu","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingsheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,7]]},"reference":[{"issue":"3","key":"3251_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169\u2013181. https:\/\/doi.org\/10.1038\/nrc2088","journal-title":"Nat Rev Cancer"},{"issue":"7153","key":"3251_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561\u2013566. https:\/\/doi.org\/10.1038\/nature05945","journal-title":"Nature"},{"issue":"1","key":"3251_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","volume":"18","author":"A Drilon","year":"2021","unstructured":"Drilon A, Jenkins C, Iyer S et al (2021) ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat Rev Clin Oncol 18(1):35\u201355. https:\/\/doi.org\/10.1038\/s41571-020-0408-9","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"3251_CR4","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/modpathol.2011.109","volume":"24","author":"SI Chiosea","year":"2011","unstructured":"Chiosea SI, Sherer CK, Jelic T et al (2011) KRAS mutant allele-specific imbalance in lung adenocarcinoma. Mod Pathol 24(12):1571\u20131577. https:\/\/doi.org\/10.1038\/modpathol.2011.109","journal-title":"Mod Pathol"},{"issue":"9","key":"3251_CR5","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069\u20131086. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367","journal-title":"Cancer Discov"},{"key":"3251_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3760\/cma.j.cn112152-20201009-00884","volume":"43","author":"Chinese Association for Clinical Oncologists and Medical Oncology Branch of Chinese International Exchange; Promotion Association for Medical and Healthcare","year":"2021","unstructured":"Chinese Association for Clinical Oncologists and Medical Oncology Branch of Chinese International Exchange; Promotion Association for Medical and Healthcare (2021) Clinical practice guideline for stage IV primary lung cancer in China (2021 version). Zhonghua zhong liu za zhi [Chin J Oncol] 43:39\u201359. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20201009-00884","journal-title":"Zhonghua zhong liu za zhi [Chin J Oncol]"},{"issue":"21","key":"3251_CR7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"key":"3251_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.critrevonc.2019.07.004","volume":"142","author":"AR Almutairi","year":"2019","unstructured":"Almutairi AR, Alkhatib N, Martin J et al (2019) Comparative efficacy and safety of immunotherapies targeting the PD-1\/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Crit Rev Oncol Hematol 142:16\u201325. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.004","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"3251_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","volume":"7","author":"S Zhao","year":"2019","unstructured":"Zhao S, Ren S, Jiang T et al (2019) Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer. Cancer Immunol Res 7(4):630\u2013643. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0640","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"3251_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","volume":"20","author":"RS Herbst","year":"2019","unstructured":"Herbst RS, Arkenau HT, Santana-Davila R et al (2019) Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial. Lancet Oncol 20(8):1109\u20131123. https:\/\/doi.org\/10.1016\/S1470-2045(19)30458-9","journal-title":"Lancet Oncol"},{"issue":"4","key":"3251_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","volume":"16","author":"T Chu","year":"2021","unstructured":"Chu T, Zhong R, Zhong H et al (2021) Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol 16(4):643\u2013652. https:\/\/doi.org\/10.1016\/j.jtho.2020.11.026","journal-title":"J Thorac Oncol"},{"issue":"5","key":"3251_CR12","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-20-3136","volume":"27","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wang Y, Zhao J et al (2021) Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy. Clin Cancer Res 27(5):1296\u20131304. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3136","journal-title":"Clin Cancer Res"},{"issue":"7637","key":"3251_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer\u2013immune set point. Nature 541(7637):321\u2013330. https:\/\/doi.org\/10.1038\/nature21349","journal-title":"Nature"},{"issue":"2","key":"3251_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Au JS, Thongprasert S et al (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9(2):154\u2013162. https:\/\/doi.org\/10.1097\/JTO.0000000000000033","journal-title":"J Thorac Oncol"},{"issue":"11","key":"3251_CR15","doi-asserted-by":"publisher","first-page":"e0143515","DOI":"10.1371\/journal.pone.0143515","volume":"10","author":"Y Shi","year":"2015","unstructured":"Shi Y, Li J, Zhang S et al (2015) Molecular epidemiology of EGFR mutations in asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - mainland china subset analysis of the PIONEER study. PLoS ONE 10(11):e0143515. https:\/\/doi.org\/10.1371\/journal.pone.0143515","journal-title":"PLoS ONE"},{"issue":"5","key":"3251_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","volume":"14","author":"YL Wu","year":"2019","unstructured":"Wu YL, Lu S, Cheng Y et al (2019) Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol 14(5):867\u2013875. https:\/\/doi.org\/10.1016\/j.jtho.2019.01.006","journal-title":"J Thorac Oncol"},{"issue":"8","key":"3251_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(20)30329-6","volume":"21","author":"DW Wu","year":"2020","unstructured":"Wu DW, Huang HY, Tang Y et al (2020) Clinical development of immuno-oncology in China. Lancet Oncol 21(8):1013\u20131016. https:\/\/doi.org\/10.1016\/S1470-2045(20)30329-6","journal-title":"Lancet Oncol"},{"issue":"10183","key":"3251_CR18","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819\u20131830. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"3251_CR19","doi-asserted-by":"publisher","first-page":"10333","DOI":"10.2147\/CMAR.S280096","volume":"12","author":"S Yang","year":"2020","unstructured":"Yang S, Zhang W, Chen Q et al (2020) Clinical investigation of the efficacy and safety of anlotinib with immunotherapy in advanced non-small cell lung cancer as third-line therapy: a retrospective study. Cancer Manag Res 12:10333\u201310340. https:\/\/doi.org\/10.2147\/CMAR.S280096","journal-title":"Cancer Manag Res"},{"key":"3251_CR20","doi-asserted-by":"publisher","first-page":"619010","DOI":"10.3389\/fonc.2020.619010","volume":"10","author":"C Zhai","year":"2021","unstructured":"Zhai C, Zhang X, Ren L et al (2021) The efficacy and safety of anlotinib combined with PD-1 antibody for third-line or further-line treatment of patients with advanced non-small-cell lung cancer. Front Oncol 10:619010. https:\/\/doi.org\/10.3389\/fonc.2020.619010","journal-title":"Front Oncol"},{"key":"3251_CR21","doi-asserted-by":"publisher","first-page":"628124","DOI":"10.3389\/fonc.2021.628124","volume":"11","author":"P Wang","year":"2021","unstructured":"Wang P, Fang X, Yin T et al (2021) Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study. Front Oncol 11:628124. https:\/\/doi.org\/10.3389\/fonc.2021.628124","journal-title":"Front Oncol"},{"key":"3251_CR22","doi-asserted-by":"publisher","first-page":"175883592093033","DOI":"10.1177\/1758835920930333","volume":"12","author":"R Jin","year":"2020","unstructured":"Jin R, Zhao J, Xia L et al (2020) Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. Ther Adv Med Oncol 12:1758835920930333. https:\/\/doi.org\/10.1177\/1758835920930333","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3251_CR23","doi-asserted-by":"publisher","first-page":"16902","DOI":"10.1038\/s41598-019-52913-z","volume":"9","author":"F Guisier","year":"2019","unstructured":"Guisier F, Cousse S, Jeanvoine M et al (2019) A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer. Sci Rep 9(1):16902. https:\/\/doi.org\/10.1038\/s41598-019-52913-z","journal-title":"Sci Rep"},{"issue":"2","key":"3251_CR24","doi-asserted-by":"publisher","first-page":"e000645","DOI":"10.1136\/jitc-2020-000645","volume":"8","author":"D Chardin","year":"2020","unstructured":"Chardin D, Paquet M, Schiappa R et al (2020) Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. J Immunother Cancer 8(2):e000645. https:\/\/doi.org\/10.1136\/jitc-2020-000645","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3251_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-014-0040-2","volume":"2","author":"M Nishino","year":"2014","unstructured":"Nishino M, Giobbie-Hurder A, Ramaiya NH et al (2014) Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer 2(1):40. https:\/\/doi.org\/10.1186\/s40425-014-0040-2","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3251_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak S, Ten Dijke P (2017) Targeting TGF-\u03b2 signaling in cancer. Trends Cancer 3(1):56\u201371. https:\/\/doi.org\/10.1016\/j.trecan.2016.11.008","journal-title":"Trends Cancer"},{"issue":"5","key":"3251_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/cbt.19594","volume":"13","author":"C Aggarwal","year":"2012","unstructured":"Aggarwal C, Somaiah N, Simon G (2012) Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther 13(5):247\u2013263. https:\/\/doi.org\/10.4161\/cbt.19594","journal-title":"Cancer Biol Ther"},{"issue":"24","key":"3251_CR28","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542\u20132550. https:\/\/doi.org\/10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"issue":"1","key":"3251_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D et al (2018) Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 11(1):120. https:\/\/doi.org\/10.1186\/s13045-018-0664-7","journal-title":"J Hematol Oncol"},{"key":"3251_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/1471-2407-10-529","volume":"10","author":"J Li","year":"2010","unstructured":"Li J, Zhao X, Chen L et al (2010) Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 10:529. https:\/\/doi.org\/10.1186\/1471-2407-10-529","journal-title":"BMC Cancer"},{"issue":"1","key":"3251_CR31","doi-asserted-by":"publisher","first-page":"15837","DOI":"10.1038\/s41598-018-34030-5","volume":"8","author":"Y Jin","year":"2018","unstructured":"Jin Y, Wei L, Jiang Q et al (2018) Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model. Sci Rep 8(1):15837. https:\/\/doi.org\/10.1038\/s41598-018-34030-5","journal-title":"Sci Rep"},{"issue":"7223","key":"3251_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/nature07424","volume":"456","author":"JI Greenberg","year":"2008","unstructured":"Greenberg JI, Shields DJ, Barillas SG et al (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456(7223):809\u2013813. https:\/\/doi.org\/10.1038\/nature07424","journal-title":"Nature"},{"issue":"3","key":"3251_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1172\/JCI25705","volume":"116","author":"X Xian","year":"2006","unstructured":"Xian X, H\u00e5kansson J, St\u00e5hlberg A et al (2006) Pericytes limit tumor cell metastasis. J Clin Invest 116(3):642\u2013651. https:\/\/doi.org\/10.1172\/JCI25705","journal-title":"J Clin Invest"},{"issue":"2","key":"3251_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.canlet.2013.03.005","volume":"335","author":"J Garc\u00eda-Rom\u00e1n","year":"2013","unstructured":"Garc\u00eda-Rom\u00e1n J, Zentella-Dehesa A (2013) Vascular permeability changes involved in tumor metastasis. Cancer Lett 335(2):259\u2013269. https:\/\/doi.org\/10.1016\/j.canlet.2013.03.005","journal-title":"Cancer Lett"},{"key":"3251_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1478-811X-11-97","volume":"11","author":"CH Heldin","year":"2013","unstructured":"Heldin CH (2013) Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 11:97. https:\/\/doi.org\/10.1186\/1478-811X-11-97","journal-title":"Cell Commun Signal"},{"issue":"1","key":"3251_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40880-016-0123-1","volume":"35","author":"I Fuso Nerini","year":"2016","unstructured":"Fuso Nerini I, Cesca M, Bizzaro F et al (2016) Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin J Cancer 35(1):61. https:\/\/doi.org\/10.1186\/s40880-016-0123-1","journal-title":"Chin J Cancer"},{"issue":"5","key":"3251_CR37","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26(5):605\u2013622. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.006","journal-title":"Cancer Cell"},{"issue":"5","key":"3251_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z et al (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15(5):325\u2013340. https:\/\/doi.org\/10.1038\/nrclinonc.2018.29","journal-title":"Nat Rev Clin Oncol"},{"issue":"28","key":"3251_CR39","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"7","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA et al (2019) Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 7(28):2518\u20132527. https:\/\/doi.org\/10.1200\/JCO.19.00934","journal-title":"J Clin Oncol"},{"issue":"7","key":"3251_CR40","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE et al (2021) Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 39(7):723\u2013733. https:\/\/doi.org\/10.1200\/JCO.20.01605","journal-title":"J Clin Oncol"},{"issue":"4","key":"3251_CR41","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H et al (2018) Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 109(4):1207\u20131219. https:\/\/doi.org\/10.1111\/cas.13536","journal-title":"Cancer Sci"},{"issue":"7","key":"3251_CR42","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","volume":"102","author":"S Tian","year":"2011","unstructured":"Tian S, Quan H, Xie C et al (2011) YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 102(7):1374\u20131380. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.01939.x","journal-title":"Cancer Sci"},{"issue":"7","key":"3251_CR43","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.3390\/ijms22073765","volume":"22","author":"F Lopes-Coelho","year":"2021","unstructured":"Lopes-Coelho F, Martins F, Pereira SA et al (2021) Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci 22(7):3765. https:\/\/doi.org\/10.3390\/ijms22073765","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3251_CR44","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1200\/JCO.2009.25.4482","volume":"28","author":"SE Dahlberg","year":"2010","unstructured":"Dahlberg SE, Sandler AB, Brahmer JR et al (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28(6):949\u2013954. https:\/\/doi.org\/10.1200\/JCO.2009.25.4482","journal-title":"J Clin Oncol"},{"issue":"11","key":"3251_CR45","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/annonc\/mdq221","volume":"21","author":"R Goodwin","year":"2010","unstructured":"Goodwin R, Ding K, Seymour L et al (2010) Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 21(11):2220\u20132226. https:\/\/doi.org\/10.1093\/annonc\/mdq221","journal-title":"Ann Oncol"},{"issue":"11","key":"3251_CR46","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1172\/JCI119451","volume":"99","author":"M Ziche","year":"1997","unstructured":"Ziche M, Morbidelli L, Choudhuri R et al (1997) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99(11):2625\u20132634. https:\/\/doi.org\/10.1172\/JCI119451","journal-title":"J Clin Invest"},{"issue":"3","key":"3251_CR47","doi-asserted-by":"publisher","first-page":"H1054","DOI":"10.1152\/ajpheart.1998.274.3.H1054","volume":"74","author":"JD Hood","year":"1998","unstructured":"Hood JD, Meininger CJ, Ziche M et al (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 74(3):H1054\u2013H1058. https:\/\/doi.org\/10.1152\/ajpheart.1998.274.3.H1054","journal-title":"Am J Physiol"},{"issue":"8","key":"3251_CR48","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/01.hjh.0000174970.56965.4f","volume":"23","author":"A Bobik","year":"2005","unstructured":"Bobik A (2005) The structural basis of hypertension: vascular remodelling, rarefaction and angiogenesis\/arteriogenesis. J Hypertens 23(8):1473\u20131475. https:\/\/doi.org\/10.1097\/01.hjh.0000174970.56965.4f","journal-title":"J Hypertens"},{"issue":"12","key":"3251_CR49","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96(12):1788\u20131795. https:\/\/doi.org\/10.1038\/sj.bjc.6603813","journal-title":"Br J Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03251-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03251-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03251-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T14:04:55Z","timestamp":1674482695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03251-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,7]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3251"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03251-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,7]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no competing interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This was a retrospective study and approved by the Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}